knowledge -WSS

knowledge

author：Wikipedia 2025-09-27 23:00:52 - browse：79

Most everything is looking up for Orexo, the company reported on its second quarter earnings call on Tuesday. That is, everything but its digital therapies pipeline.

The Swedish pharmaceutical company, which makes almost all of its money from U.S. sales of its drug for opioid dependence, notched a number of important victories in the quarter: It successfully defended its patents in a case against Sun Pharmaceuticals, it resolved a packaging issue that was holding up the approval of its long-acting rescue medication, and it grew revenues for Zubsolv, its most important product. The company trimmed its losses to 12.6 million SEK, or $1.2 million, and executives reported that with fewer one-time expenses on the horizon, profitability was “in sight.”

“We are at an exciting turning point for the company and I hope our self confidence and optimism is something that you can share,” CEO Nikolaj Sørensen said on the company’s earnings call while cautioning that “there’s a lot more work to be done.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Stopping antidepressants leads to symptoms for 1 in 6 patients

knowledge

WSS

Radiology is caught between AI's potential and concern for patients

How CO2 helps viruses stay alive longer in the air

Congenital heart disease patients face new threat of heart failure

For pregnant people, addiction treatment shouldn't mean a call to child protective services

STAT Health News: mRNA flu shots, Purdue SCOTUS case, etc

Finland to offer bird flu vaccine to select groups of people, a possible global first

explore

knowledge

Wikipedia

Trump demands the U.S. pay no more for drugs than other countries … again

Roche to buy Carmot Therapeutics, developer of obesity drugs

FDA approval of Sarepta Duchenne genetic therapy gives me hope

SCOTUS to consider access to abortion pill mifepristone

As demand for Covid shots wanes, Moderna seeks its next success

'Little Tech' descents on D.C., wanting a say in how AI is regulated

BioMarin wins approval for gene therapy to treat hemophilia A

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

BioMarin wins approval for gene therapy to treat hemophilia A

Sanofi says it has 12 blockbusters on the way. Will investors believe it?

explore

After sickle

An outdated Medicare rule harms dementia patients with anxiety

Radiology is caught between AI's potential and concern for patients

UnitedHealth CEO's Medicaid comments send insurer stocks diving

STAT letters to the editor on burnt

STAT Health News: mRNA flu shots, Purdue SCOTUS case, etc

focus

Wikipedia

knowledge

leisure time